Who holds the pegloticase patent, and what is it covering?
Pegloticase is an enzyme therapy product (pegylated uricase). Patent coverage typically sits with the drug’s developer and later assignees covering key aspects such as the pegloticase molecule (including pegylation/variants), pharmaceutical formulations, and manufacturing methods. However, which specific patents are “the pegloticase patent” depends on the particular product claim family and jurisdiction (US vs. EP vs. JP), and on whether you mean the foundational composition patent or later method/formulation/improvement patents.
If you tell me the country (e.g., US) and the product name you’re seeing (brand/generic), I can narrow to the most relevant patent family and document numbers.
When does pegloticase patent protection expire?
Patent expiry depends on multiple factors: the priority date of the earliest filed patent in the family, national patent term rules, and any patent term adjustments or extensions. For biologics/biopharmaceuticals like pegloticase, practical market exclusivity can also extend beyond the first “patent expiry” date due to regulatory exclusivity mechanisms in the relevant country.
To answer precisely, I need jurisdiction (US/Europe/UK/etc.) and whether you want legal patent expiry, regulatory exclusivity expiry, or both.
Are there any pegloticase biosimilar or “generic” timelines?
“Generic” versions are not usually the right framing for enzyme/biologic therapies; biosimilar-style pathways apply in many markets. The timing for entry generally depends on when the relevant patents and any regulatory exclusivity end, and whether biosimilar makers can avoid infringement of the protected claims.
If you want, share your target market (US vs EU) and I can map the typical entry gates: patent expiry, regulatory exclusivity, and likely litigation windows.
Can another company challenge the pegloticase patents?
Yes, patent challenges commonly happen through:
- Post-grant procedures in the issuing jurisdiction (for example, reexamination/Inter partes review-like mechanisms in the US), and/or
- In litigation around alleged infringement by an applicant’s proposed product.
The specific pegloticase patents that get challenged—and the grounds (invalidity, non-infringement, claim construction)—are document- and jurisdiction-specific. Providing the patent number(s) you’re looking at would let me explain the posture and what’s been argued.
What if I’m looking for a specific pegloticase patent number?
People often search with partial names like “pegloticase patent” when they actually want one of:
- the earliest composition-of-matter patent,
- later formulation/manufacturing patents,
- a patent listed in regulatory patent registries (market-authorization dependent),
- a patent involved in a dispute.
Paste any of the following and I’ll identify what it covers and when it expires:
- country/jurisdiction
- patent number (e.g., USxxxxxxx)
- application number
- a link or screenshot text from the listing you found
Sources
I don’t have any pegloticase patent documents or dates in the information provided to me here, so I can’t accurately cite specific patent numbers or expiry timelines without you sharing a jurisdiction or a patent identifier.